Bước đầu khảo sát mối liên quan giữa đa hình rs505151 gen PCSK9 và rối loạn lipid máu ở người bệnh thận mạn giai đoạn cuối lọc máu chu kỳ

Abstract

The PCSK9 gene plays an important role in lipid metabolism, but evidence regarding the association between the rs505151 polymorphism and dyslipidemia in patients with end-stage chronic kidney disease (ESCKD) remains limited. This descriptive cross-sectional study was conducted on 103 patients with ESCKD undergoing maintenance hemodialysis between May 2025 and December 2025 to characterize the genotype distribution of the PCSK9 rs505151 polymorphism and examine its association with serum lipid parameters. The AA genotype was predominant, accounting for 92.2% of the study population, whereas the heterozygous AG genotype accounted for 7.8%, with a G allele frequency of 3.9%. No GG genotype was identified. The overall prevalence of dyslipidemia was 95.1% and reduced HDL-C was the most common abnormality at 74.5%. Patients carrying the AG genotype had higher levels of TC, LDL-C, and non-HDL-C compared with those with the AA genotype (p < 0.05). In multivariable linear regression analysis, the G allele of the PCSK9 rs505151 polymorphism suggested an independent association with several lipid components in patients with ESCKD undergoing maintenance hemodialysis. These findings should be confirmed in studies with larger sample sizes and longitudinal designs.